Journal article
Spending and Utilization for Chronic Rhinosinusitis With Nasal Polyps Therapies Among Commercially Insured Beneficiaries
The Laryngoscope, v 135(5), pp 1537-1539
May 2025
PMID: 40026190
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The Food and Drug Administration (FDA) recently approved several novel therapies to treat chronic rhinosinusitis with nasal polyps (CRSwNP), though high prices may burden patients and payers. CRSwNP‐specific spending varied widely by prescription drug among commercially insured patients, ranging from$7050 (EDS‐FLU) to $ 28,324 (dupilumab). Condition‐specific costs owed out‐of‐pocket ranged from$1036 (other drugs) to $ 3549 (mepolizumab).
Metrics
1 Record Views
Details
- Title
- Spending and Utilization for Chronic Rhinosinusitis With Nasal Polyps Therapies Among Commercially Insured Beneficiaries
- Creators
- Akash M. Bhat - Medical University of South CarolinaRodney J. Schlosser - Medical University of South CarolinaZachary M. Soler - Medical University of South CarolinaVinay K. Rathi (Corresponding Author) - The Ohio State University
- Publication Details
- The Laryngoscope, v 135(5), pp 1537-1539
- Publisher
- Wiley
- Number of pages
- 3
- Grant note
- OptiNose
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Otolaryngology (and Head and Neck Surgery)
- Web of Science ID
- WOS:001435975000001
- Scopus ID
- 2-s2.0-85219075535
- Other Identifier
- 991022197401104721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Medicine, Research & Experimental
- Otorhinolaryngology